Inhibikase Therapeutics (IKT) Free Cash Flow (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Free Cash Flow for 7 consecutive years, with -$12.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow fell 192.93% year-over-year to -$12.1 million; the TTM figure through Mar 2026 stood at -$35.7 million (down 84.26% YoY), while the FY2025 annual figure was -$27.8 million, down 45.18% from the prior year.
• Free Cash Flow retreated to -$12.1 million in Q1 2026 per IKT's latest filing, from -$7.5 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$3.4 million in Q4 2023 and bottomed at -$12.1 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$5.6 million across 5 years, with a median of -$4.9 million in 2024.
• Annual changes were most pronounced in 2024 — Free Cash Flow jumped 35.25% — and 2026, when it slumped 192.93%.
• Inhibikase Therapeutics' Free Cash Flow stood at -$3.6 million in 2022, then grew by 3.2% to -$3.4 million in 2023, then plunged by 55.28% to -$5.3 million in 2024, then slumped by 40.6% to -$7.5 million in 2025, then tumbled by 60.45% to -$12.1 million in 2026.
• Business Quant data shows IKT's Free Cash Flow at -$12.1 million in Q1 2026, -$7.5 million in Q4 2025, and -$10.6 million in Q3 2025.